Welcome to BioSeeker Group!

Welcome to the Drug Pipeline Update Series - Area Specific Drug Analysis

BioSeeker's Drug Pipeline Updates contain world-wide and detailed drug pipeline information for a selected cancer indication area or mechanism of action area.

Our Drug Pipeline Update products serve executives in the pharmaceutical, biotech, and financial industries. BioSeeker provides an unbiased, accurate, independent approach to pipeline analysis, for competitive, partnering or investment purposes.

BioSeeker covers more than 10,500 drugs across 200 indications in oncology via our intuitive guided searches, innovative filters, and the result presented in smart, online reports available for download. Each drug profile is a synopsis of the history of the drug, from companies involved in the drug’s discovery and development, patent protection, target/ MoA, compound structures, indications in development, to details on discovery-stage, and pre-clinical data & clinical development, including ongoing & completed clinical trials.

The Drug Pipeline Update Series is available via almost 100 sector specific products (see the full list below), or for full coverage of all 10,500+ drugs, as the Drug Pipeline Update™ (Free Sample Pages are available on request).

How May Drug Pipeline Update Be of Use?

Show investors/board/management that you are right on top of drug development progress in your therapeutic area.

Find competitors, collaborations partners, M&A candidates etc.

Jump start competitive drug intelligence operations

Excellent starting point for world wide benchmarking

Compare portfolio and therapy focus with your peers

Speed up pro-active in-/outlicensing strategy work

Drug repositioning

Fast and easy way of tracking drugs using search engines; with just one click you may search the entire Internet or PubMed for any drug with all its synonyms.

Stay Updated for Free

Find your Pipeline report in cancer and stay updated through one year of free online updates.
You can keep yourself abreast with future development as we include one year of free data and functionality updates in your purchase of the Drug Pipeline Update. After one year you can subscribe for another year of updates at very favorable rates.

 

Dynamic Report Generator

Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer), whether it is a single drug profile or a report the results of an entire search.

For a Single Drug Profile – Just click on any drug name on your hit list
For a Report on the full found set – Make your search and then click on the “Generate HTML Report for all Found Drugs” button and all found drugs will be presented in alphabetical order with a table of contents page giving quick links to all included drugs.

 

Export & Visualize Your Findings

Our included visualization and export package enables you to effortlessly make use of any retrieved data into tables and figures for both online and offline presentations, making it easy to communicate your findings to your peers.







 

Good to know...

BioSeeker’s Drug Pipeline Update products are desktop apps for specific interests/needs in oncology.
When you require a holistic oncology source of information and analysis please consider our Oncology Drug Pipeline Update™ (Premium) service and any of our other solutions like Oncology Drug Pathway Analyzer™ (Premium) and Cancer Highlights™. These three products are also available as one service through our 1stOncology™ platform for drug analytics in oncology. Please download our one page brochure for further information.

  1. 2015 BIO Asia Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Mar 9th, 2015
    BioSeeker Group have identified at least 75 companies represented at the 2015 BIO Asia meeting linked to the active development of 816 drugs in 3,092 developmental projects in cancer across 413 different targets. Learn More

  2. Adherens Junction Targeting in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 277 companies plus partners who are today developing 357 targeting adherens junctions drugs in 1199 developmental projects in cancer across 134 different targets. In addition, there is 1 suspended drug and another 136 drugs where development has been ceased. Learn More

  3. Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 378 companies plus partners who are today developing 534 Alpha6Beta4 integrin pathway targeting drugs in 1796 developmental projects in cancer across 186 different targets. In addition, there is 1 suspended drug and another 209 drugs where development has been ceased. Learn More

  4. Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 455 companies plus partners who are today developing 569 Androgen Receptor drugs in 1838 developmental projects in cancer across 228 different targets. In addition, there are 2 suspended drugs and another 258 drugs where development has been ceased. Learn More

  5. Angiogenesis in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 389 companies plus partners who are today developing 428 angiogenesis drugs in 1991 developmental projects in cancer across 288 different targets. In addition, there are 7 suspended drugs and another 218 drugs where development has been ceased. Learn More

  6. Antibodies in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 542 companies plus partners who are today developing 1308 antibody drugs in 3051 developmental projects in cancer across 414 different targets. In addition, there are 4 suspended drugs and another 407 drugs where development has been ceased. Learn More

  7. Apoptosis in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 460 companies plus partners who are today developing 588 apoptotic drugs in 2586 developmental projects in cancer across 389 different targets. In addition, there are 13 suspended drugs and another 307 drugs where development has been ceased. Learn More

  8. B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 309 companies plus partners who are today developing 424 B cell receptor pathway targeting drugs in 1700 developmental projects in cancer across 198 different targets. In addition, there are 5 suspended drugs and another 154 drugs where development has been ceased. Learn More

  9. Bio-Europe 2014 Cancer Drug Pipeline Update 2015

    $4,425.00
    Published by BioSeeker Group on Jan 5th, 2015
    BioSeeker Group have identified 292 companies plus partners who are today developing 1381 BIO-Europe 2014 cancer drugs in 4487 developmental projects in cancer across 629 different targets. In addition, there are 18 suspended drugs and another 880 drugs where development has been ceased. Learn More

  10. Biologicals in Oncology Drug Pipeline Update

    $3,675.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 1371 companies plus partners who are today developing 2823 biological drugs in 6088 developmental projects in cancer across 801 different targets. In addition, there are 25 suspended drugs and another 1050 drugs where development has been ceased. Learn More

  11. Biosimilars in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 90 companies plus partners who are today developing 213 biosimilar drugs in 472 developmental projects in cancer across 17 different targets. In addition, there is 1 suspended drug and another 1 drugs where development has been ceased. Learn More

  12. Bladder Cancer Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 139 companies plus partners who are today developing 152 drugs targeting bladder cancer in development. across 142 different targets. In addition, there are 3 suspended drugs and another 42 drugs where development has been ceased. Learn More

  13. Brain Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 333 companies plus partners who are today developing 397 drugs targeting brain cancer in development. across 225 different targets. In addition, there are 2 suspended drugs and another 96 drugs where development has been ceased. Learn More

  14. Breast Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 636 companies plus partners who are today developing 706 drugs targeting breast cancer in development. across 469 different targets. In addition, there are 7 suspended drugs and another 242 drugs where development has been ceased. Learn More

  15. Calcium Signaling Pathway in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 276 companies plus partners who are today developing 335 calcium signaling pathway targeting drugs in 1110 developmental projects in cancer across 145 different targets. In addition, there is 1 suspended drug and another 130 drugs where development has been ceased. Learn More

  16. Cancer Drugs in the FDA Fast Lane Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 142 companies plus partners who are today developing 171 cancer drugs in the FDA fast lane drugs in 1660 developmental projects in cancer across 177 different targets. In addition, there are 7 suspended drugs and another 65 drugs where development has been ceased. Learn More

  17. Cancer Stem Cells Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 441 companies plus partners who are today developing 648 cancer stem cells and developmental pathways drugs in 2272 developmental projects in cancer across 329 different targets. In addition, there are 6 suspended drugs and another 308 drugs where development has been ceased. Learn More

  18. Cancer Vaccines Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 314 companies plus partners who are today developing 386 cancer vaccine drugs in 784 developmental projects in cancer across 195 different targets. In addition, there are 8 suspended drugs and another 208 drugs where development has been ceased. Learn More

  19. Cell Cycle Targeting in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 180 companies plus partners who are today developing 190 targeting the cell cycle drugs in 687 developmental projects in cancer across 131 different targets. In addition, there are 2 suspended drugs and another 123 drugs where development has been ceased. Learn More

  20. Cellular Therapy in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 164 companies plus partners who are today developing 272 cellular therapy drugs in 577 developmental projects in cancer across 92 different targets. In addition, there are 7 suspended drugs and another 66 drugs where development has been ceased. Learn More

  21. Chemokine Signaling Pathway in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 232 companies plus partners who are today developing 323 chemokine signaling pathway targeting drugs in 1189 developmental projects in cancer across 177 different targets. In addition, there are 3 suspended drugs and another 127 drugs where development has been ceased. Learn More

  22. Colorectal Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 426 companies plus partners who are today developing 509 drugs targeting colorectal cancer in development. across 346 different targets. In addition, there are 6 suspended drugs and another 211 drugs where development has been ceased. Learn More

  23. Conjugated Drugs in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 295 companies plus partners who are today developing 451 conjugated drugs in oncology drugs in 1015 developmental projects in cancer across 238 different targets. In addition, there are 2 suspended drugs and another 145 drugs where development has been ceased. Learn More

  24. Cytokine Therapy in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 80 companies plus partners who are today developing 99 cytokine drugs in 195 developmental projects in cancer across 20 different targets. In addition, there is 1 suspended drug and another 11 drugs where development has been ceased. Learn More

  25. Drug Target Atlas in Oncology

    $7,950.00
    Published by BioSeeker Group on Aug 9th, 2016
    System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
    - Browser Application (Internet Explorer)
    - Internet access (to access related internet resources)
    Learn More

  26. EGFR1 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 554 companies plus partners who are today developing 852 EGFR1 pathway targeting drugs in 3067 developmental projects in cancer across 295 different targets. In addition, there are 5 suspended drugs and another 379 drugs where development has been ceased. Learn More

  27. Epigenetic Therapy in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 101 companies plus partners who are today developing 129 epigenetic therapy drugs in 477 developmental projects in cancer across 57 different targets. In addition, there is 1 suspended drug and another 36 drugs where development has been ceased. Learn More

  28. ErbB Signaling Pathway in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 366 companies plus partners who are today developing 528 ErbB signaling pathway targeting drugs in 1896 developmental projects in cancer across 187 different targets. In addition, there is 1 suspended drug and another 202 drugs where development has been ceased. Learn More

  29. Fc Epsilon RI Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 182 companies plus partners who are today developing 255 Fc epsilon RI signaling pathway targeting drugs in 966 developmental projects in cancer across 148 different targets. In addition, there are 2 suspended drugs and another 84 drugs where development has been ceased. Learn More

  30. Fierce 15 in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 72 companies plus partners who are today developing 201 Fierce 15 drugs in 600 developmental projects in cancer across 130 different targets. In addition, there are 2 suspended drugs and another 34 drugs where development has been ceased. Learn More

  31. FSH Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 273 companies plus partners who are today developing 369 FSH pathway targeting drugs in 1441 developmental projects in cancer across 165 different targets. In addition, there are 2 suspended drugs and another 167 drugs where development has been ceased. Learn More

  32. Gap Junctions in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 280 companies plus partners who are today developing 396 gap junctions targeting drugs in 1561 developmental projects in cancer across 170 different targets. In addition, there is 1 suspended drug and another 167 drugs where development has been ceased. Learn More

  33. Gene Therapy in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 125 companies plus partners who are today developing 103 gene therapy drugs in 262 developmental projects in cancer across 107 different targets. In addition, there are 4 suspended drugs and another 105 drugs where development has been ceased. Learn More

  34. GnRH Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 185 companies plus partners who are today developing 234 GnRH signaling pathway targeting drugs in 844 developmental projects in cancer across 126 different targets. In addition, there is 1 suspended drug and another 86 drugs where development has been ceased. Learn More

  35. Head and Neck Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 214 companies plus partners who are today developing 236 drugs targeting head and neck cancer in development. across 222 different targets. In addition, there are 2 suspended drugs and another 59 drugs where development has been ceased. Learn More

  36. Hedgehog Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 163 companies plus partners who are today developing 203 Hedgehog pathway targeting drugs in 883 developmental projects in cancer across 133 different targets. In addition, there are 3 suspended drugs and another 90 drugs where development has been ceased. Learn More

  37. Hematological Cancers Drug Pipeline Update

    $2,950.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 700 companies plus partners who are today developing 1147 hematological cancer drugs in 2542 developmental projects in cancer across 485 different targets. In addition, there are 12 suspended drugs and another 308 drugs where development has been ceased. Learn More

  38. HIF-1 Signaling Pathway in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 478 companies plus partners who are today developing 658 HIF-1 signaling pathway targeting drugs in 2402 developmental projects in cancer across 236 different targets. In addition, there are 4 suspended drugs and another 246 drugs where development has been ceased. Learn More

  39. ID Signaling Pathway in Oncology Drug Pipeline Update

    $750.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 117 companies plus partners who are today developing 114 ID pathway targeting drugs in 493 developmental projects in cancer across 104 different targets. In addition, there is 1 suspended drug and another 62 drugs where development has been ceased. Learn More

  40. IL-1 Signaling Pathway in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 111 companies plus partners who are today developing 113 IL-1 pathway targeting drugs in 415 developmental projects in cancer across 96 different targets. In addition, there are 2 suspended drugs and another 55 drugs where development has been ceased. Learn More

  41. IL-2 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 344 companies plus partners who are today developing 449 IL-2 pathway targeting drugs in 1619 developmental projects in cancer across 192 different targets. In addition, there are 6 suspended drugs and another 183 drugs where development has been ceased. Learn More

  42. IL-3 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 257 companies plus partners who are today developing 339 IL-3 pathway targeting drugs in 1225 developmental projects in cancer across 164 different targets. In addition, there are 4 suspended drugs and another 131 drugs where development has been ceased. Learn More

  43. IL-4 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 208 companies plus partners who are today developing 274 IL-4 pathway targeting drugs in 988 developmental projects in cancer across 161 different targets. In addition, there are 4 suspended drugs and another 105 drugs where development has been ceased. Learn More

  44. IL-5 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 163 companies plus partners who are today developing 209 IL-5 pathway targeting drugs in 891 developmental projects in cancer across 146 different targets. In addition, there are 2 suspended drugs and another 86 drugs where development has been ceased. Learn More

  45. IL-6 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 378 companies plus partners who are today developing 467 IL-6 pathway targeting drugs in 1579 developmental projects in cancer across 198 different targets. In addition, there are 2 suspended drugs and another 203 drugs where development has been ceased. Learn More

  46. IL-7 Signaling Pathway in Oncology Drug Pipeline Update

    $750.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 90 companies plus partners who are today developing 95 IL-7 pathway targeting drugs in 389 developmental projects in cancer across 85 different targets. In addition, there is 1 suspended drug and another 36 drugs where development has been ceased. Learn More

  47. IL-9 Signaling Pathway in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 83 companies plus partners who are today developing 88 IL-9 pathway targeting drugs in 366 developmental projects in cancer across 67 different targets. In addition, there is 1 suspended drug and another 35 drugs where development has been ceased. Learn More

  48. Immunotherapy in Oncology Drug Pipeline Update

    $3,675.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 830 companies plus partners who are today developing 1578 cancer immunotherapy drugs in 4062 developmental projects in cancer across 535 different targets. In addition, there are 19 suspended drugs and another 624 drugs where development has been ceased. Learn More

  49. Interfering With Cytokine-Cytokine Receptor Interaction for the Treatment of Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 529 companies plus partners who are today developing 854 cytokine-cytokine receptor interaction interference drugs in 2473 developmental projects in cancer across 310 different targets. In addition, there are 10 suspended drugs and another 303 drugs where development has been ceased. Learn More

  50. Interfering With the ECM-Receptor Interaction for the Treatment of Cancer Drug Pipeline Update

    $750.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 67 companies plus partners who are today developing 50 targeting ECM-receptor interaction drugs in 121 developmental projects in cancer across 52 different targets. In addition, there is 1 suspended drug and another 28 drugs where development has been ceased. Learn More

  51. Jak-STAT Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 341 companies plus partners who are today developing 473 Jak-STAT signaling pathway targeting drugs in 1185 developmental projects in cancer across 203 different targets. In addition, there are 8 suspended drugs and another 141 drugs where development has been ceased. Learn More

  52. Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 248 companies plus partners who are today developing 346 Kit receptor pathway targeting drugs in 1506 developmental projects in cancer across 178 different targets. In addition, there are 3 suspended drugs and another 176 drugs where development has been ceased. Learn More

  53. Leptin Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 410 companies plus partners who are today developing 537 Leptin pathway targeting drugs in 1840 developmental projects in cancer across 213 different targets. In addition, there are 3 suspended drugs and another 229 drugs where development has been ceased. Learn More

  54. Leukemia Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 456 companies plus partners who are today developing 631 leukemia drugs in 913 developmental projects in cancer across 333 different targets. In addition, there are 8 suspended drugs and another 164 drugs where development has been ceased. Learn More

  55. Liver Cancer Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 260 companies plus partners who are today developing 280 drugs targeting liver cancer in development. across 221 different targets. In addition, there is 1 suspended drug and another 65 drugs where development has been ceased. Learn More

  56. Lung Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 552 companies plus partners who are today developing 809 lung cancer drugs in 884 developmental projects in cancer across 431 different targets. In addition, there are 10 suspended drugs and another 267 drugs where development has been ceased. Learn More

  57. Lymphoma Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 383 companies plus partners who are today developing 568 lymphoma drugs in 1073 developmental projects in cancer across 302 different targets. In addition, there are 4 suspended drugs and another 143 drugs where development has been ceased. Learn More

  58. Melanoma Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 374 companies plus partners who are today developing 403 drugs targeting melanoma in development. across 317 different targets. In addition, there are 2 suspended drugs and another 155 drugs where development has been ceased. Learn More

  59. MicroRNAs in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 567 companies plus partners who are today developing 841 microRNA targeting and competitor drugs in 3023 developmental projects in cancer across 289 different targets. In addition, there are 5 suspended drugs and another 343 drugs where development has been ceased. Learn More

  60. Mitochondrial Drugs in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 341 companies plus partners who are today developing 373 mitochondrial drugs in oncology drugs in 1212 developmental projects in cancer across 223 different targets. In addition, there are 5 suspended drugs and another 156 drugs where development has been ceased. Learn More

  61. Modulators of the Actin Cytoskeleton for the Treatment of Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 280 companies plus partners who are today developing 427 targeting actin cytoskeleton modulators drugs in 1598 developmental projects in cancer across 187 different targets. In addition, there is 1 suspended drug and another 178 drugs where development has been ceased. Learn More

  62. mTOR Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 221 companies plus partners who are today developing 278 mTOR signaling pathway targeting drugs in 1136 developmental projects in cancer across 127 different targets. In addition, there is 1 suspended drug and another 89 drugs where development has been ceased. Learn More

  63. Neuroendocrine Tumors Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 121 companies plus partners who are today developing 138 neuroendocrine tumor drugs in 199 developmental projects in cancer across 122 different targets. In addition, there is 1 suspended drug and another 24 drugs where development has been ceased. Learn More

  64. NOD-like Receptor Signaling Pathway in Cancer Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 113 companies plus partners who are today developing 88 NOD-like receptor signaling pathway targeting drugs in 272 developmental projects in cancer across 95 different targets. In addition, there is 1 suspended drug and another 58 drugs where development has been ceased. Learn More

  65. Notch Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 335 companies plus partners who are today developing 416 Notch pathway targeting drugs in 1497 developmental projects in cancer across 232 different targets. In addition, there are 4 suspended drugs and another 236 drugs where development has been ceased. Learn More

  66. Nucleic Acid Therapies in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 308 companies plus partners who are today developing 381 nucleic acid therapy drugs in 775 developmental projects in cancer across 251 different targets. In addition, there are 9 suspended drugs and another 211 drugs where development has been ceased. Learn More

  67. Oncology Drug Pipeline Update - Desktop App

    $14,850.00
    Published by BioSeeker Group on Mar 25th, 2014
    Get desktop access to competitive drug information formore than 9,300 drugs across 200+ indications in oncology via our intuitive guided searches, innovative filters, and the result presented in smart reports. Learn More

  68. Oncology Drug Pipeline Update - Online

    $7,950.00
    Published by BioSeeker Group on Jan 1st, 2016
    Get online access to competitive drug information for more than 10,500 drugs across 200+ indications in oncology via our intuitive guided searches, innovative filters, and the result presented in smart, online reports available for download. Learn More

  69. Orphan Drugs in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 476 companies plus partners who are today developing 665 orphan drugs in oncology drugs in 4085 developmental projects in cancer across 422 different targets. In addition, there are 15 suspended drugs and another 190 drugs where development has been ceased. Learn More

  70. Ovarian Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 357 companies plus partners who are today developing 438 drugs targeting ovarian cancer in development. across 307 different targets. In addition, there are 6 suspended drugs and another 124 drugs where development has been ceased. Learn More

  71. p53 Signaling Pathway in Cancer Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 120 companies plus partners who are today developing 108 p53 signaling pathway targeting drugs in 340 developmental projects in cancer across 84 different targets. In addition, there is 1 suspended drug and another 67 drugs where development has been ceased. Learn More

  72. Pancreatic Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 385 companies plus partners who are today developing 444 drugs targeting pancreatic cancer in development. across 352 different targets. In addition, there is 1 suspended drug and another 136 drugs where development has been ceased. Learn More

  73. Peptides in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 340 companies plus partners who are today developing 356 peptide drugs in 778 developmental projects in cancer across 252 different targets. In addition, there are 4 suspended drugs and another 148 drugs where development has been ceased. Learn More

  74. PI3K-Akt Signaling Pathway in Cancer Drug Pipeline Update

    $2,999.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 678 companies plus partners who are today developing 1154 PI3K-Akt signaling pathway targeting drugs in 3721 developmental projects in cancer across 349 different targets. In addition, there are 12 suspended drugs and another 452 drugs where development has been ceased. Learn More

  75. Prostate Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 462 companies plus partners who are today developing 469 drugs targeting prostate cancer in development. across 350 different targets. In addition, there are 4 suspended drugs and another 231 drugs where development has been ceased. Learn More

  76. Protein Kinase Inhibitors in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 462 companies plus partners who are today developing 831 PKI drugs in 2912 developmental projects in cancer across 296 different targets. In addition, there are 5 suspended drugs and another 459 drugs where development has been ceased. Learn More

  77. Proteins in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 455 companies plus partners who are today developing 521 protein drugs in 914 developmental projects in cancer across 229 different targets. In addition, there are 2 suspended drugs and another 207 drugs where development has been ceased. Learn More

  78. Radiation Therapy in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 322 companies plus partners who are today developing 313 radiation therapy drugs in 692 developmental projects in cancer across 179 different targets. In addition, there are 7 suspended drugs and another 150 drugs where development has been ceased. Learn More

  79. RANKL Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 282 companies plus partners who are today developing 356 RANKL pathway targeting drugs in 1398 developmental projects in cancer across 155 different targets. In addition, there is 1 suspended drug and another 178 drugs where development has been ceased. Learn More

  80. Renal Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 243 companies plus partners who are today developing 270 drugs targeting renal cancer in development. across 233 different targets. In addition, there are 3 suspended drugs and another 95 drugs where development has been ceased. Learn More

  81. RIG-I-like Receptor Signaling Pathway in Cancer Drug Pipeline Update

    $750.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 78 companies plus partners who are today developing 55 RIG-I-like receptor signaling pathway targeting drugs in 166 developmental projects in cancer across 85 different targets. In addition, there is 1 suspended drug and another 33 drugs where development has been ceased. Learn More

  82. RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 103 companies plus partners who are today developing 131 RNA (miRNA, RNAi & siRNA) drugs in 198 developmental projects in cancer across 103 different targets. In addition, there are 2 suspended drugs and another 39 drugs where development has been ceased. Learn More

  83. T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 355 companies plus partners who are today developing 469 T cell receptor pathway targeting drugs in 1756 developmental projects in cancer across 242 different targets. In addition, there are 7 suspended drugs and another 210 drugs where development has been ceased. Learn More

  84. Targeting Cell Adhesion Molecules (CAMs) for the Treatment of Cancer Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 146 companies plus partners who are today developing 182 targeting CAMs drugs in 706 developmental projects in cancer across 124 different targets. In addition, there are 3 suspended drugs and another 49 drugs where development has been ceased. Learn More

  85. Targeting Focal Adhesion for the Treatment of Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 488 companies plus partners who are today developing 739 focal adhesion targeting drugs in 2727 developmental projects in cancer across 268 different targets. In addition, there are 5 suspended drugs and another 315 drugs where development has been ceased. Learn More

  86. Targeting Immune Checkpoints in Cancer Immunotherapy Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 120 companies plus partners who are today developing 227 immune checkpoints drugs in 835 developmental projects in cancer across 71 different targets. In addition, there are 4 suspended drugs and another 19 drugs where development has been ceased. Learn More

  87. Targeting Metabolic Pathways in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 221 companies plus partners who are today developing 235 metabolic pathways targeting drugs in 590 developmental projects in cancer across 157 different targets. In addition, there are 2 suspended drugs and another 92 drugs where development has been ceased. Learn More

  88. Targeting Natural Killer Cell Mediated Cytotoxicity in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 252 companies plus partners who are today developing 318 targeting natural killer cell mediated cytotoxicity drugs in 1129 developmental projects in cancer across 179 different targets. In addition, there are 2 suspended drugs and another 95 drugs where development has been ceased. Learn More

  89. Targeting Tight Junctions in Cancer Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 120 companies plus partners who are today developing 122 tight junction targeting drugs in 466 developmental projects in cancer across 107 different targets. In addition, there is 1 suspended drug and another 48 drugs where development has been ceased. Learn More

  90. TCR/CAR-T Therapies in Oncology Drug Pipeline Update

    $995.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 40 companies plus partners who are today developing 124 TCR/CAR-T drugs in 300 developmental projects in cancer across 58 different targets. In addition, there is 1 suspended drug and another 1 drugs where development has been ceased. Learn More

  91. TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 396 companies plus partners who are today developing 509 TGF-beta receptor pathway targeting drugs in 1845 developmental projects in cancer across 259 different targets. In addition, there are 2 suspended drugs and another 265 drugs where development has been ceased. Learn More

  92. The Latest Sales Figures in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 46 companies plus partners who are today developing 114 The Latest Sales Figures in Oncology drugs in 1477 developmental projects in cancer across 113 different targets. In addition, there are 2 suspended drugs and another 27 drugs where development has been ceased. Learn More

  93. The MAPK Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 343 companies plus partners who are today developing 463 The MAPK signaling pathway targeting drugs in 1699 developmental projects in cancer across 206 different targets. In addition, there are 2 suspended drugs and another 198 drugs where development has been ceased. Learn More

  94. TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 534 companies plus partners who are today developing 731 TNF-alpha pathway targeting drugs in 2597 developmental projects in cancer across 286 different targets. In addition, there are 5 suspended drugs and another 313 drugs where development has been ceased. Learn More

  95. Toll-Like Receptor Signaling Pathway in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 238 companies plus partners who are today developing 301 Toll-like Receptor signaling pathway targeting drugs in 996 developmental projects in cancer across 177 different targets. In addition, there are 6 suspended drugs and another 110 drugs where development has been ceased. Learn More

  96. Transcriptional Misregulation in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 292 companies plus partners who are today developing 350 transcriptional misregulation targeting drugs in 1432 developmental projects in cancer across 229 different targets. In addition, there are 6 suspended drugs and another 204 drugs where development has been ceased. Learn More

  97. TSH Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 226 companies plus partners who are today developing 315 TSH pathway targeting drugs in 1330 developmental projects in cancer across 183 different targets. In addition, there are 4 suspended drugs and another 150 drugs where development has been ceased. Learn More

  98. TSLP Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 248 companies plus partners who are today developing 306 TSLP pathway targeting drugs in 1255 developmental projects in cancer across 179 different targets. In addition, there are 2 suspended drugs and another 174 drugs where development has been ceased. Learn More

  99. VEGF Signaling Pathway in Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 253 companies plus partners who are today developing 348 VEGF signaling pathway targeting drugs in 1433 developmental projects in cancer across 164 different targets. In addition, there are 3 suspended drugs and another 151 drugs where development has been ceased. Learn More

  100. Viral Carcinogenesis Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 246 companies plus partners who are today developing 311 viral carcinogenesis targeting drugs in 1170 developmental projects in cancer across 169 different targets. In addition, there is 1 suspended drug and another 138 drugs where development has been ceased. Learn More

  101. Wnt Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 228 companies plus partners who are today developing 253 Wnt pathway targeting drugs in 935 developmental projects in cancer across 204 different targets. In addition, there are 2 suspended drugs and another 118 drugs where development has been ceased. Learn More

101 Item(s)

per page

Set Descending Direction